

Managing Patients With Neurotrophic Keratitis:

Improve outcomes through recognition, applying updated staging, evidence-based treatment and team-based follow-up



References

1. Bian Y, Ma KK, Hall NE, et al. Neurotrophic keratopathy in the United States: An Intelligent Research in Sight Registry analysis. *Ophthalmology*. 2022;129(11):1255-1262. doi:10.1016/j.ophtha.2022.06.019
2. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. *Eye (Lond)*. 2003;17(8):989-995. doi:10.1038/sj.eye.6700616
3. Cenegermin-bkbj. REDBOOK Online. IBM Micromedex [database online]. Truven Health Analytics/IBM Watson Health; 2024.
4. Dai X, Jensen A, Dun C, Karakus S, Rajaii F, Woreta F. Cost and prescriber and patient characteristics of cenegermin use in the Medicare population. *Am J Ophthalmol*. 2023;250:12-19. doi:10.1016/j.ajo.2023.01.025
5. Dompé. Storing Oxervate. Accessed May 15, 2024. <https://oxervate.com/getting-and-storing-oxervate/>
6. Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. *Prog Retin Eye Res*. 2018;66:107-131. doi:10.1016/j.preteyeres.2018.04.003
7. Golebiowski B, Papas E, Stapleton F. Assessing the sensory function of the ocular surface: implications of use of a non-contact air jet aesthesiometer versus the Cochet-Bonnet aesthesiometer. *Exp Eye Res*. 2011;92(5):408-413. doi:10.1016/j.exer.2011.02.016
8. Koay SY, Larkin DFP. New pharmacological approaches for the treatment of neurotrophic keratitis. *Front Pharmacol*. 2022;13:796854. doi:10.3389/fphar.2022.796854
9. Mackie IA. Neuroparalytic keratitis. In: Fraunfelder F, Roy FH, Meyer SM (eds). *Current Ocular Therapy*. Philadelphia, PA: WB Saunders, 1995: 452-454.
10. Murray LT, McCormack J, Grobeiu I, Wiklund I, Kimel M, Van Nooten F. Development of the neurotrophic keratopathy questionnaire: qualitative research. *J Patient Rep Outcomes*. 2020;4(1):30. doi:10.1186/s41687-020-00192-y
11. Neurotrophic Keratopathy Study Group. Neurotrophic keratopathy: An updated understanding. *Ocul Surf*. 2023;30:129-138. doi:10.1016/j.jtos.2023.09.001
12. Oxervate. Prescribing information. Dompé U.S. Inc. Accessed May 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761094s012s013lbl.pdf
13. Park JK, Charlson ES, Leyngold I, Kossler AL. Corneal neurotization: A review of pathophysiology and outcomes. *Ophthalmic Plast Reconstr Surg*. 2020;36(5):431-437. doi:10.1097/IOP.0000000000001583
14. Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial. *Ophthalmology*. 2020;127(1):14-26. doi:10.1016/j.ophtha.2019.08.020
15. Sheha H, Tighe S, Hashem O, Hayashida Y. Update on cenegermin eye drops in the treatment of neurotrophic keratitis. *Clin Ophthalmol*. 2019;13:1973-1980. doi:10.2147/OPHTH.S185184
16. Vera-Duarte GR, Jimenez-Collado D, Kahuam-López N, et al. Neurotrophic keratopathy: General features and new therapies. *Surv Ophthalmol*. doi:10.1016/j.survophthal.2024.04.004
17. Wróbel-Dudzińska D, Alio J, Rodriguez A, et al. Clinical efficacy of platelet-rich plasma in the treatment of neurotrophic corneal ulcer. *J Ophthalmol*. 2018;2018:3538764. doi:10.1155/2018/3538764